Figure: Transcatheter aortic valve replacement (TAVR)
Aortic Valve Replacement (TAVR), also referred as Transcatheter Aortic
Valve Implantation (TAVI) is a minimally invasive surgical procedure
repairs the valve without removing the old, damaged valve. Instead, it
wedges a replacement valve into the aortic valve’s place. Normally valve
replacement method requires an open heart procedure with a sternotomy,
in which the chest is surgically separated for the treatment. Whereas,
the TAVR procedures can be done through very small openings that leave
all the chest bones in place. There are two methods available for TAVR
surgical procedure, which includes:
through the femoral artery (large artery in the groin), called the
transfemoral approach, which does not require a surgical incision in the
minimally invasive surgical approach with a small incision in the chest
and entering through a large artery in the chest or through the tip of
the left ventricle (the apex), which is known as the transapical
clinical trials on TAVR devices proved that these devices are
non-inferior, and possibly superior, to Surgical Aortic Valve
Replacement (SAVR) within the intermediate risk patient population.
These trials were also noteworthy for the low complication rates
observed in the TAVR groups. As TVAR’s application moves from inoperable
and high risk patients to patients who have moderate or lower risk for
open heart surgery, the market will expand exponentially in the coming
of the key driving factors attributing to the growth of this market
include increasing number of patients with cardiovascular diseases such
as hypertension, heart failures and coronary artery diseases. In
addition, increasing adoption of minimally invasive procedures over
traditional surgical open heart procedures, reduction in hospital stays,
low risk of infection, minimal blood loss are further propelling the
market. According to World Health Organization (WHO), it has been
estimated that the number of people suffering from cardiovascular
diseases will increase to 22.2 million by 2030. The market for TAVR is
expected to reach around USD 6.5 billion by 2022, growing at a CAGR of
21.3% during the forecast period of 2016e to 2022f. However, there are
certain restraining factors which could hamper the growth of this
market, which includes, high costs associated with the LAVD implantation
compared to other therapies available for CVD diseases. A TAVR device
costs USD 30,000, which is six times the price of the average surgical
valve. In addition, for a hospital to be reimbursed for a TAVR
procedure, the patient must be evaluated by a multidisciplinary team
that involves multiple cardiac surgeons and interventional
cardiologists. However, there are some cost savings compared to surgery,
such as shorter length of stay in the hospital.
North America is leading contributor to the market and is expected to
retain its position during the forecast period. Nonetheless, the market
for Asia-Pacific region is expected to grow at a faster rate owing to
increasing prevalence of CVD diseases, growing awareness about minimally
invasive surgical procedures among the population, improving healthcare
infrastructure, rise in healthcare spending, and favorable government
- Edwards Lifesciences Corp.
- Boston Scientific Corp.
- Direct Flow medical, Inc.
- Bracco SpA.
- JenaValve Technology, Inc.
- Medtronic plc
- Meril Life Sciences Pvt. Ltd.
- Jude Medical, Inc.
- Transcatheter Technologies GmbH.
report delivers a strategic analysis of the global market for TAVRs and
growth forecast for the period from 2016e – 2022f. The scope of the
report includes competitive analysis of various market players who are
operating in the market, segmental analysis based on type of indication.
It also covers geographical analysis of the market with growth forecast
for the period of 2016e – 2022f. The Porter’s Five Forces analysis and
value chain analysis included in the report provides an insight into
market dynamics and industry competition.
study also provides information for recent merger and acquisition deals
happened in the global TAVR market. Moreover, the report also includes
growth strategies and entry barriers to be considered to cater to the
exact business opportunities in this market. Additionally, to aid in
strategic decision making, the report also includes competitive
profiling of leading players, recent developments in the industry and
various business strategies adopted by them. This report will help
players in global TAVR market to plan and implement their strategies in
different market areas such as emerging geographies, and new
1. Scope of the report
1.1 Report description
1.2 Research methodology
1.3 List of abbreviations
1.4 Market segmentation
2. Executive summary
3. Qualitative analysis
3.1 Market overview
3.2 Value chain analysis
3.3 Porters five forces analysis
3.4 Key M&A trends and strategic partnerships
3.5 Competitive matrix of the key companies
4. Global TAVR market, by type of treatment, 2016 - 2022
4.1 Transfemoral approach
4.2 Transapical approach
5. Global TAVR market, by geography, 2016 - 2022
5.1 North America
5.4 Rest of the World
6. Company profiles
6.1 Edwards Lifesciences Corp.
6.2 Boston Scientific Corp.
6.3 Direct Flow medical, Inc.
6.4 Bracco SpA
6.5 JenaValve Technology, Inc.
6.6 Medtronic plc
6.7 St. Jude Medical Inc.
6.8 Meril Life Sciences Pvt. Ltd.
6.9 Transcatheter Technologies GmbH